Andrew Strickland

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Marc Peeters, Timothy Price, Andrés Cervantes et al. · Journal of Clinical Oncology · 2010 · 1K citations

Medicine, Oncology, Pharmacology +15

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Guy A. Van Hazel, Volker Heinemann, Navesh Sharma et al. · Journal of Clinical Oncology · 2016 · 348 citations

Medicine, Oncology, Radiation Oncology +17

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Nick Pavlakis, Katrin Marie Sjoquist, Andrew Martin et al. · Journal of Clinical Oncology · 2016 · 243 citations · Full text

Medicine, Oncology, Pharmacology +10